Boeing Co. (BA US): The world's second-largest commercial-
plane maker and Textron Inc. (TXT US) received a $10.4 billion
contract for the V-22 Osprey that ensures production of 167 more
of the aircraft through 2012. Boeing fell 1 percent to $73.47,
while Textron gained 0.7 percent to $54.62 on March 28.
Citigroup Inc. (C US): The company, battling to restore
profit after a record loss, will set up an independent credit-
card unit and overhaul consumer banking along geographical lines.
Citigroup lost 4.4 percent to $20.83 on March 28.
Clear Channel Communications Inc. (CCU US) lost 0.8 percent
to $28.96 in Germany. The largest U.S. radio broadcaster deferred
its first-quarter dividend after a dispute with lenders delayed
the closing of its $19.5 billion acquisition by Bain Capital LLC
and Thomas H. Lee Partners LP.
Conseco Inc. (CNO US) lost 1.4 percent to $10.26 in Germany.
The life insurer said its net loss was $194 million last year,
less than the $210.1 million deficit the company reported when it
released preliminary results on March 17.
Gilat Satellite Networks Ltd. (GILT US) rose 3.4 percent to
$10.80. The Israeli maker of satellite equipment will be bought
by an investment group led by Gores Group LLC and Mivtach Shamir
Holdings Ltd. for $11.40 a share.
Lee Enterprises Inc. (LEE US) dropped 1.4 percent to $10.61
in Germany. The publisher of 50 daily newspapers will record a
$500 million to $700 million expense for the quarter that ended
yesterday to reflect the declining value of its publications.
Lehman Brothers Holdings Inc. (LEH US) lost 1.5 percent to
$37.32. The fourth-largest U.S. securities firm sued Marubeni
Corp. (8002 JT) to recover 35.2 billion yen ($353 million),
claiming it was the victim of a six-month fraud involving
employees at the Japanese trading company that included forged
documents and a phony executive.
Merck & Co. (MRK US) fell 11 percent to $39.70. Schering-
Plough Corp. (SGP US) retreated 20 percent to $15.65. Their
cholesterol pill Vytorin didn't slow clogging of the arteries
better than an older, cheaper drug, prompting doctors to say the
medicine should be used only as a last resort.
